The clinical translation of 99mTc-, 18F- and 68Ga-labeled prostate specific membrane antigen (PSMA)-targeting tracers for single-photon emission tomography (SPECT) or positron emission tomography (PET) are considered a significant step forward for the diagnostics of prostate cancer (PCa) [1–5]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.